Vitiligo beyond the skin: the melanocytes in your eyes and ears

Almost every conversation about vitiligo is a conversation about visible skin. Where the patches are, whether they are spreading, what will bring the color back, what to do about the sun. It is a reasonable focus. It is also incomplete in a specific way that most patients never hear about, and the omission is not because the information is obscure. It is because the information is contested.

Melanocytes, the cells destroyed in vitiligo, are not confined to skin. They are present in the uveal tract and retinal pigment epithelium of the eye, and in the stria vascularis of the inner ear, where they play a role in maintaining the fluid chemistry that hearing depends on. If the disease process in vitiligo is an immune attack on melanocytes, the obvious question is whether it stops at the skin.

The original element in this piece is a direct comparison of what two very different kinds of study report on this question, and an explicit account of where they disagree and why. These findings are published separately, in different journals, using different methods, and nobody sets them side by side for patients. Set side by side, they resolve into a much more useful answer than either one gives alone.

The two bodies of evidence. The first kind is the clinical case control study: take a group of people with vitiligo, take a matched group without it, run detailed eye and hearing testing on everyone, and count differences. A case control study of ocular and auditory abnormalities in patients with vitiligo is representative of this design. Studies of this type consistently find measurable abnormalities at higher rates in vitiligo, and the abnormalities they find are frequently subtle: pigment changes in the retina or iris found on examination, and hearing differences that show up on audiometry rather than as a complaint.

The second kind is the population registry study: take national health data covering millions of people, identify everyone coded with vitiligo, and compare rates of diagnosed eye and ear conditions against everyone else. A nationwide population based study of ocular and auditory comorbidities in vitiligo in the Republic of Korea is that design. These studies capture diagnoses that entered a medical record, which means they capture conditions that were symptomatic enough for someone to seek care.

Where they disagree, and why it is not a contradiction. The case control studies find abnormalities in a substantial fraction of patients. Registry studies find elevated risk, but the absolute rates of diagnosed disease are far lower than the rates of detected abnormality.

Read carelessly, that looks like conflict. It is not. The two designs are measuring different things. A screening study looking hard at everyone finds subclinical findings, meaning changes detectable by an instrument that the person has not noticed and that are not affecting their life. A registry study finds clinical disease, meaning something that made a person go to a doctor. The gap between those two numbers is the population of people who have a detectable finding that is not currently causing them a problem.

Both are true. The honest summary is that measurable involvement of ocular and auditory melanocytes is common in vitiligo, and that clinically significant disease from it is much less common. That sentence, which no single paper says, is what a patient actually needs.

The third thread worth knowing is that vitiligo sits inside a broader autoimmune picture, described in work framing vitiligo as part of a systemic autoimmune process. The best established of those associations is thyroid, which is why the thyroid connection has become part of routine care in a way the eye and ear findings have not.

What this changes about your appointments. Very little, and the little it changes is worth doing.

You do not need urgent specialist referral because you have vitiligo. There is no guideline recommending routine ophthalmology or audiology screening for everyone with the condition, and the evidence above is the reason: subclinical findings that do not progress to symptomatic disease in most people do not meet the bar for population screening.

What is reasonable is to be a slightly better historian. Get an eye examination on a normal adult schedule and mention the vitiligo, because it costs nothing for the examiner to know, and it puts an incidental pigment finding into context rather than leaving it as a mystery. Do the same at any hearing test. And treat new symptoms as worth reporting rather than dismissing: persistent light sensitivity, eye pain or redness, a change in vision, new tinnitus, or hearing that has shifted. Those are worth an appointment in anyone, and in a person with vitiligo they have a plausible mechanism behind them rather than being random.

Two situations deserve a lower threshold. Extensive or rapidly progressive disease, since the burden of melanocyte loss is greater. And any vitiligo affecting the eyelids or the area around the eyes, simply because the examination is easy to arrange while you are already discussing that region.

What the studies do not tell you. Three gaps stand out. Nobody has followed a cohort of people with subclinical retinal or audiometric findings over years to see whether those findings progress, stay stable, or resolve. Without that, the clinical meaning of a subclinical finding is genuinely unknown, and any clinician who tells you confidently that it is nothing, or that it is a warning sign, is going beyond the evidence in either direction.

Second, the rates reported vary considerably between studies, and much of that variance is method. Different testing protocols, different thresholds for calling something abnormal, and different populations produce different numbers, so a single percentage quoted from a single paper is not a fact about vitiligo generally.

Third, almost none of this work separates segmental vitiligo from generalized disease, even though the two behave differently in nearly every other respect and there is a reasonable mechanistic argument that they should differ here as well.

The takeaway. Vitiligo is a disease of melanocytes, and melanocytes live in more places than skin. The measurable footprint of that is broad and the symptomatic footprint is narrow, and the distance between those two facts is where most of the alarming things patients read online come from. You do not need to be screened. You do need to know that a new eye or ear symptom has somewhere to go in the conversation, rather than being filed under unrelated. That, and knowing that your dermatologist's usual thyroid check exists for the same underlying reason, is the whole practical content of this.